Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Fei Hong / Toppari, Jorma / Turan, Serap Demircioglu

IMPACT FACTOR 2018: 1.239

CiteScore 2018: 1.22

SCImago Journal Rank (SJR) 2018: 0.507
Source Normalized Impact per Paper (SNIP) 2018: 0.562

See all formats and pricing
More options …
Volume 29, Issue 11


Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation

Peter A. Lee
  • Corresponding author
  • Penn State School of Medicine, Milton S. Hershey Medical Center, P.O. Box 850, Hershey, PA 17033, United States of America
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Margaret Luce / Peter Bacher
Published Online: 2016-10-14 | DOI: https://doi.org/10.1515/jpem-2016-0026



Peak gonadotropin-releasing hormone or agonist (GnRHa) stimulated luteinizing hormone (LH) testing with leuprolide acetate (LA) is commonly used to document suppression during therapy for central precocious puberty (CPP). The objective of the study was to investigate suitability of using basal LH levels to monitor GnRHa treatment and to determine optimal transition from 1-month to 3-month LA formulations via a post hoc analysis of a randomized, open-label, 6-month study.


A total of 42 children with CPP, pretreated with 7.5-, 11.25-, or 15-mg 1-month LA formulations were randomized to 11.25- or 30-mg 3-month LA. Basal LH/peak-stimulated LH levels were measured at weeks 0, 4, 8 and 12. Positive/negative predictive values and sensitivities/specificities were determined for basal LH vs. LH-stimulation results.


Pretreatment with any 1-month formulation for the most part did not affect continuation of suppression after transitioning to 3-month formulation (mean peak-stimulated LH levels remained < 4 IU/L). Basal LH predicted suppression escape (basal LH-level cutoff ≥ 0.6 IU/L predicted 70% of those failing suppression). Tolerability was similar, regardless of dose.


Our data indicate that a basal level of <0.60 IU/L is adequate for monitoring suppression approximately two-thirds of the time. Furthermore, the effectiveness and safety of 3-month LA treatments are not influenced by previous CPP therapies.

Keywords: gonadotropin-releasing hormone; leuprolide acetate; luteinizing hormone; puberty, precocious


  • 1.

    Menon PS, Vijayakumar M. Precocious puberty-perspectives on diagnosis and management. Indian J Pediatr 2014;81:76–83.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 2.

    Lee PA. Central precocious puberty. An overview of diagnosis, treatment, and outcome. Endocrinol Metab Clin North Am 1999;28:901–18, xi.CrossrefGoogle Scholar

  • 3.

    Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. Hum Reprod Update 2004;10:135–47.CrossrefPubMedGoogle Scholar

  • 4.

    Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, et al. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of decapeptyl in precocious puberty. J Clin Endocrinol Metab 1999;84:1973–8.CrossrefGoogle Scholar

  • 5.

    Lebrethon MC, Bourguignon JP. Management of central isosexual precocity: diagnosis, treatment, outcome. Curr Opin Pediatr 2000;12:394–9.PubMedCrossrefGoogle Scholar

  • 6.

    Mul D, Hughes IA. The use of GnRH agonists in precocious puberty. Eur J Endocrinol 2008;159(Suppl 1):S3–8.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 7.

    Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752–62.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 8.

    AbbVie Inc. Lupron-Depot-PED® (leuprolide acetate for depot suspension): prescribing Information. North Chicago, IL: AbbVie, Inc., 2013.Google Scholar

  • 9.

    Lee PA, Klein K, Mauras N, Neely EK, Bloch CA, et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab 2012;97:1572–80.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 10.

    Lee PA, Klein K, Mauras N, Lev-Vaisler T, Bacher P. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. J Clin Endocrinol Metab 2014;99:3153–9.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 11.

    Neely EK, Hintz RL, Wilson DM, Lee PA, Gautier T, et al. Normal ranges for immunochemiluminometric gonadotropin assays. J Pediatr 1995;127:40–6.PubMedCrossrefGoogle Scholar

  • 12.

    Neely EK, Wilson DM, Lee PA, Stene M, Hintz RL. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr 1995;127:47–52.CrossrefPubMedGoogle Scholar

  • 13.

    Brito VN, Batista MC, Borges MF, Latronico AC, Kohek MB, et al. Diagnostic value of fluorometric assays in the evaluation of precocious puberty. J Clin Endocrinol Metab 1999;84:3539–44.PubMedGoogle Scholar

  • 14.

    Houk CP, Kunselman AR, Lee PA. Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls. Pediatrics 2009;123:e1059–63.Web of SciencePubMedCrossrefGoogle Scholar

  • 15.

    Lewis KA, Eugster EA. Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty. J Pediatr 2013;162:562–5.CrossrefPubMedGoogle Scholar

  • 16.

    Neely EK, Silverman LA, Geffner ME, Danoff TM, Gould E, et al. Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy. Int J Pediatr Endocrinol 2013;2013:20.PubMedCrossrefGoogle Scholar

  • 17.

    Roche AF, Chumlea WC, Thissen D. Assessing the skeletal maturity of the hand-wrist: FELS method. Springfield, IL: Charles C Thomas Pub Ltd, 1988.Google Scholar

  • 18.

    Resende EA, Lara BH, Reis JD, Ferreira BP, Pereira GA, et al. Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J Clin Endocrinol Metab 2007;92:1424–9.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 19.

    Neely EK, Hintz RL, Parker B, Bachrach LK, Cohen P, et al. Two-year results of treatment with depot leuprolide acetate for central precocious puberty. J Pediatr 1992;121:634–40.CrossrefPubMedGoogle Scholar

About the article

Corresponding author: Peter A. Lee, MD, PhD, Penn State School of Medicine, Milton S. Hershey Medical Center, P.O. Box 850, Hershey, PA 17033, USA, Fax: +717-531-6139

Received: 2016-01-18

Accepted: 2016-08-29

Published Online: 2016-10-14

Published in Print: 2016-11-01

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: This study was funded by AbbVie.

Employment or leadership: PB is an employee of AbbVie. At the time of the study, ML was an intern at AbbVie.

Honorarium: PL has received research support and honoraria as a member of a speaker’s bureau for AbbVie. He has also received honoraria from Novo Nordisk as a consultant and as a member of a medical advisory board.

Competing interests: AbbVie was involved in study design, research, analysis, data collection, interpretation of data, and writing, reviewing, and approval of the article.

Citation Information: Journal of Pediatric Endocrinology and Metabolism, Volume 29, Issue 11, Pages 1249–1257, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: https://doi.org/10.1515/jpem-2016-0026.

Export Citation

©2016 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in